India  

Pfizer vaccine is 94% effective in real-world study

Video Credit: Reuters Studio - Duration: 01:47s - Published
Pfizer vaccine is 94% effective in real-world study

Pfizer vaccine is 94% effective in real-world study

The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.

Gloria Tso reports.


You Might Like


💡 newsR Knowledge: Other News Mentions

Pfizer Pfizer American multinational pharmaceutical corporation

Pfizer offers COVID-19 vaccine to India at 'not-for-profit' price

The company also said that it would supply the Pfizer-bayonet COVID-19 mRNA vaccine only through a government contract.
DNA

Covid-19: Private hospital chains in talks to offer imported vaccines

Private hospital chains across the country, including the Chennai-based Apollo group and Delhi-based Fortis Healthcare, and Mumbai-based Hinduja Hospital, are..
IndiaTimes

Covid-19: Pfizer vaccine partially effective against Indian variant

Israel has registered eight cases of a coronavirus variant first identified in India and believes that the Pfizer/BioNTech vaccine is at least partially..
IndiaTimes
Maharashtra govt took decision to use imported vaccines Sputnik V, Pfizer: Rajesh Tope [Video]

Maharashtra govt took decision to use imported vaccines Sputnik V, Pfizer: Rajesh Tope

Maharashtra Health Minister Rajesh Tope on April 20 informed that the state government has not yet received any letter from Centre about vaccination program for those above 18 years. However, CM Uddhav Thackeray has said that vaccination drive will be conducted in full swing. "Decision has been taken to use imported vaccines Sputnik V, Pfizer," said Rajesh Tope.

Credit: ANI    Duration: 01:50Published

BioNTech BioNTech German biotechnology company

U.S. preparing for COVID-19 booster within a year [Video]

U.S. preparing for COVID-19 booster within a year

The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against COVID-19, a White House official said on Thursday. Jayson Albano reports.

Credit: Reuters - Politics    Duration: 01:23Published
Pfizer Says COVID-19 Vaccine Protection Lasts at Least 6 Months [Video]

Pfizer Says COVID-19 Vaccine Protection Lasts at Least 6 Months

Pfizer and BioNTech announced that their ongoing Phase 3 clinical vaccine trial confirms protection for at least six months after the second dose.

Credit: Cover Video STUDIO    Duration: 01:00Published
Dr. Hotez on Pfizer report finding: It's pretty impressive [Video]

Dr. Hotez on Pfizer report finding: It's pretty impressive

Dr. Peter Hotez, co-director of Texas Children’s Hospital’s Center for Vaccine Development says the the clinical trial results of Pfizer/BioNTech’s Covid-19 vaccine showing 100% efficacy in youths ages 12 to 15 is “pretty impressive.”

Credit: Bleacher Report AOL    Duration: 02:01Published
BioNTech's co-founder: Vaccine protects against UK and South Africa variants [Video]

BioNTech's co-founder: Vaccine protects against UK and South Africa variants

In an exclusive interview with CNN, BioNTech co-founder and chief medical officer Özlem Türeci says her company’s coronavirus vaccine is effective against the UK variant and the South African variant.

Credit: Bleacher Report AOL    Duration: 01:15Published

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases [Video]

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults. A release by Cadila Health said, "The drug has also shown efficacy against other viral infections."Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: "The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19." This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark. India recorded 3,32,730 new COVID-19 cases in the last 24 hours, the highest single-day spike since the pandemic broke out last year. India has crossed the mark of 3 lakh COVID-19 cases for two consecutive days now. This has taken the cumulative count of the COVID infection in the country to 1,62,63,695.

Credit: ANI    Duration: 02:01Published
PM Modi holds meeting with oxygen manufacturers [Video]

PM Modi holds meeting with oxygen manufacturers

Prime Minister Narendra Modi held a meeting with oxygen manufacturers in the country via video-conferencing on April 23. The meeting was attended by Reliance, Tata Steels, SAIL, etc. Requirement of oxygen has soared in hospitals in the country due to COVID situation.

Credit: ANI    Duration: 01:13Published

Zydus Cadila gets DCGI nod for hepatitis drug for Covid-19 treatment

Drug firm Zydus Cadila on Friday said it has received restricted emergency use approval from the Indian drug regulator for the use of Pegylated Interferon..
IndiaTimes
UEFA to issue verdict on Euro 2020 hosting cities as Munich, Dublin and Bilbao face exclusion [Video]

UEFA to issue verdict on Euro 2020 hosting cities as Munich, Dublin and Bilbao face exclusion

UEFA asked hosting cities to open at least 25% of their stadiums to fans, but not all of them are able to do so amid COVID-19 restrictions.

Credit: Euronews English    Duration: 00:38Published

Related news from verified sources

Coronavirus | Large real world study confirms Pfizer COVID-19 vaccine 94% effective

The study finds out that people who received their second dose of the vaccine had a 92% lower chance...
Hindu - Published

Pfizer's COVID-19 vaccine found effective in big 'real world' test, prevents illness and death

Pfizer's COVID-19 vaccine was 92% effective at preventing severe disease after two shots and 62%...
Zee News - Published


Related videos from verified sources

UArizona-led study shows vaccinated people likely do not carry or spread virus [Video]

UArizona-led study shows vaccinated people likely do not carry or spread virus

A University of Arizona-led research study shows COVID-19 vaccines are highly effective in the real-world and vaccinated people likely do not carry or spread virus.

Credit: KGUN, Tucson, AZ     Duration: 02:15Published
Daily Covid-19 Minute: Real-World Vaccine Data [Video]

Daily Covid-19 Minute: Real-World Vaccine Data

New data proves the Pfizer and Moderna covid vaccines work extremely well in real world conditions. This from the CDC who followed over four thousand healthcare workers for 13 weeks. Among the 2500 of..

Credit: CBS 62 Detroit     Duration: 00:54Published
Study shows Pfizer vaccine effective for kids 12 to 15 [Video]

Study shows Pfizer vaccine effective for kids 12 to 15

Clinical trials show that Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in kids ages 12 to 15. Right now the vaccine is only available for people 16 and up.

Credit: KDVR     Duration: 00:14Published